| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454584 | Lung Cancer | 2016 | 8 Pages |
Abstract
Despite the difference in erlotinib exposure, there was no evidence of an incremental efficacy benefit of a higher erlotinib dose versus the standard dose in this population of highly active smokers.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Egbert F. Smit, Yi-Long Wu, Radj Gervais, Caicun Zhou, Enriqueta Felip, Jifeng Feng, Salih Zeki Guclu, Mathias Hoiczyk, Elena Dorokhova, Ulrich Freudensprung, Susan Grange, Pablo Diego Perez-Moreno, Lada Mitchell, Martin Reck,